A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented the rational design of an Alzheimer’s ...

(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern University reports that NU-9, an experimental small-molecule drug currently ...

In Alzheimer’s, a misfolded, sticky form of amyloid beta protein first groups together into small, soluble clumps called oligomers. Oligomers group together in turn to form fibrils, which then give ...